Baciewicz A M, Self T H
Arch Intern Med. 1984 Aug;144(8):1667-71. doi: 10.1001/archinte.144.8.1667.
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-450 content in the liver. Rifampin's enzyme-induction effect is selective; therefore, it is not always clear which agents will be affected. Studies and case reports have demonstrated that rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, glucocorticoids, digitoxin, quinidine, methadone, hypoglycemics, and barbiturates. Rifampin interacts with other agents, but further study is needed to demonstrate the clinical importance of these interactions. In addition to inducing drug-metabolizing enzymes, rifampin may cause alterations in absorption and hepatic uptake. Future investigations will probably identify new rifampin drug interactions.
利福平是一种抗结核药物,通常与其他抗结核药物或其他类别的药物联合使用9至12个月。由于该药物是一种强效的药物代谢诱导剂,常常存在药物相互作用的可能性。利福平会导致滑面内质网增生,并使肝脏中的细胞色素P - 450含量增加。利福平的酶诱导作用具有选择性;因此,并不总是清楚哪些药物会受到影响。研究和病例报告表明,利福平会加速多种药物的代谢,包括口服抗凝剂、口服避孕药、糖皮质激素、洋地黄毒苷、奎尼丁、美沙酮、降血糖药和巴比妥类药物。利福平与其他药物相互作用,但需要进一步研究来证明这些相互作用的临床重要性。除了诱导药物代谢酶外,利福平还可能引起吸收和肝脏摄取的改变。未来的研究可能会发现新的利福平药物相互作用。